Advertisement
KYKOF vs NVSEF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KYKOF is a Hold and NVSEF is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KYKOF’s FA Score shows that 2 FA rating(s) are green whileNVSEF’s FA Score has 3 green FA rating(s).
- KYKOF’s FA Score: 2 green, 3 red.
- NVSEF’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVSEF’s TA Score shows that 3 TA indicator(s) are bullish.
- NVSEF’s TA Score: 3 bullish, 4 bearish.
Price Growth
KYKOF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while NVSEF (@Pharmaceuticals: Major) price change was +1.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.75%. For the same industry, the average monthly price growth was +1.30%, and the average quarterly price growth was +23.81%.
Industries' Descriptions
@Pharmaceuticals: Major (+0.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| KYKOF | NVSEF | KYKOF / NVSEF | |
| Capitalization | 8.2B | 259B | 3% |
| EBITDA | 93.2B | 22.7B | 411% |
| Gain YTD | 14.200 | 32.258 | 44% |
| P/E Ratio | 35.05 | 18.53 | 189% |
| Revenue | 493B | 55.2B | 893% |
| Total Cash | 236B | 7B | 3,371% |
| Total Debt | N/A | 32.6B | - |
KYKOF | NVSEF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 98 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 29 | |
SMR RATING 1..100 | 100 | 29 | |
PRICE GROWTH RATING 1..100 | 53 | 47 | |
P/E GROWTH RATING 1..100 | 8 | 51 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVSEF's Valuation (15) in the null industry is in the same range as KYKOF (31). This means that NVSEF’s stock grew similarly to KYKOF’s over the last 12 months.
NVSEF's Profit vs Risk Rating (29) in the null industry is significantly better than the same rating for KYKOF (100). This means that NVSEF’s stock grew significantly faster than KYKOF’s over the last 12 months.
NVSEF's SMR Rating (29) in the null industry is significantly better than the same rating for KYKOF (100). This means that NVSEF’s stock grew significantly faster than KYKOF’s over the last 12 months.
NVSEF's Price Growth Rating (47) in the null industry is in the same range as KYKOF (53). This means that NVSEF’s stock grew similarly to KYKOF’s over the last 12 months.
KYKOF's P/E Growth Rating (8) in the null industry is somewhat better than the same rating for NVSEF (51). This means that KYKOF’s stock grew somewhat faster than NVSEF’s over the last 12 months.
| KYKOF | NVSEF | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 61% |
| Stochastic ODDS (%) | N/A | 2 days ago 47% |
| Momentum ODDS (%) | N/A | 2 days ago 52% |
| MACD ODDS (%) | N/A | 2 days ago 61% |
| TrendWeek ODDS (%) | 2 days ago 28% | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 26% | 2 days ago 44% |
| Advances ODDS (%) | N/A | 3 days ago 52% |
| Declines ODDS (%) | N/A | N/A |
| BollingerBands ODDS (%) | N/A | 2 days ago 45% |
| Aroon ODDS (%) | N/A | 2 days ago 35% |
Advertisement
KYKOF and
Correlation & Price change
A.I.dvisor tells us that KYKOF and OPHLY have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KYKOF and OPHLY's prices will move in lockstep.
| Ticker / NAME | Correlation To KYKOF | 1D Price Change % | ||
|---|---|---|---|---|
| KYKOF | 100% | N/A | ||
| OPHLY - KYKOF | 12% Poorly correlated | -2.11% | ||
| NVSEF - KYKOF | 7% Poorly correlated | -1.29% | ||
| GIKLY - KYKOF | 4% Poorly correlated | N/A | ||
| MAYNF - KYKOF | -1% Poorly correlated | N/A | ||
| HAWPF - KYKOF | -1% Poorly correlated | N/A | ||
More | ||||
NVSEF and
Correlation & Price change
A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.
| Ticker / NAME | Correlation To NVSEF | 1D Price Change % | ||
|---|---|---|---|---|
| NVSEF | 100% | -1.29% | ||
| SNYNF - NVSEF | 27% Poorly correlated | -5.25% | ||
| SNY - NVSEF | 21% Poorly correlated | -0.80% | ||
| NVS - NVSEF | 20% Poorly correlated | +0.58% | ||
| KYKOF - NVSEF | 7% Poorly correlated | N/A | ||
| GIKLY - NVSEF | 6% Poorly correlated | N/A | ||
More | ||||